Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacogenomics 100%
• Coronary Artery Atherosclerosis 100%
• Low Density Lipoprotein Receptor 66%
• Randomized Clinical Trial 33%
• Low Density Lipoprotein Cholesterol 33%
• Proprotein Convertase 9 33%
• Lipoprotein A 33%
• Drug Metabolizing Enzyme 33%
• Disease 33%
• Cardiovascular Disease 33%

Biochemistry, Genetics and Molecular Biology

• PCSK9 100%
• Genetic Divergence 40%
• Pharmacogenomics 30%
• Candidate Gene 20%
• Allele 20%
• Genetic Polymorphism 20%
• LDL Receptor 20%
• Genetics 10%
• Randomized Clinical Trial 10%
• Mendelian Randomization 10%
• Analytical Method 10%
• Enzyme 10%
• Lipoprotein(A) 10%
• Genetic Variation 10%
• Low-Density Lipoprotein 10%